Gene Name	Entrez ID	Drug Name	Chembl ID	Interaction Types	Sources	publications

Gene Name	Variant	Alleles	Chemical	Phenotype Category	Significance	Notes	Sentence	Publications	Annotation ID
DCTD	rs4742	GG	gemcitabine	"efficacy","toxicity"	no	Tumor response to therapy, progression free survival, and risk of neutropenia development did not significantly differ between genotype groups. This study presented this SNP as rs7663494, but dbSNP has merged that rsID with rs4742.	Genotype GG is not associated with increased response to gemcitabine in people with Pancreatic Neoplasms as compared to genotypes AA + AG.	20665488	981794086
DCTD	rs4742	AA	gemcitabine	efficacy	no	Response rate, median time to progression, and median survival time were not significantly different among patients with differing genotypes.	Genotype AA is not associated with increased response to gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AG + GG.	18538445	981785534
DCTD	rs12507552	CC	gemcitabine	efficacy	yes	Associated with longer overall survival (was not significantly associated with time to progression). Stats corrected with the false-discovery rate for candidate SNPs and Bonferroni method (p<0.05 was considered significant).	Genotype CC is associated with increased response to gemcitabine in people with Pancreatic Neoplasms as compared to genotypes CT + TT.	22838950	981237777
DCTD	rs4742	GG	ara-CTP	metabolism/PK	yes	Alleles complemented to plus chromosomal strand.	Genotype GG is associated with decreased concentrations of ara-CTP in children with Leukemia, Myeloid, Acute as compared to genotypes AA + AG.	30088438	1449752012